Just Keep Rolling?—An Encompassing Review towards Accelerated Vaccine Product Life Cycles

Abstract

In light of the recent pandemic, several COVID-19 vaccines were developed, tested and approved in a very short time, a process that otherwise takes many years. Above all, these efforts have also unmistakably revealed the capacity limits and potential for improvement in vaccine production. This review aims to emphasize recent approaches for the targeted rapid adaptation and production of vaccines from an interdisciplinary, multifaceted perspective. Using research from the literature, stakeholder analysis and a value proposition canvas, we reviewed technological innovations on the pharmacological level, formulation, validation and resilient vaccine production to supply bottlenecks and logistic networks. We identified four main drivers to accelerate the vaccine product life cycle: computerized candidate screening, modular production, digitized quality management and a resilient business model with corresponding transparent supply chains. In summary, the results presented here can serve as a guide and implementation tool for flexible, scalable vaccine production to swiftly respond to pandemic situations in the future.

Vaccine Development against Infectious Diseases: State of the Art, New Insights, and Future Directions

“…These nanoplasmids exhibit comparable transfection efficiency to conventional plasmids, making them a viable option for subunit vaccine development [15]. Insights to expedite the process of vaccine development are also discussed, aiming to offer a potential guide to produce new vaccines [16]. Lastly, the intricate landscape of vaccination during pregnancy is discussed.…”